Well, they had two deaths out of 900 patients. The two patients had cardiovascular risk factors. One died of cardiac arrest and the other cause was unknown. Let's ignore the caveats and assume the drug killed them both. There's a lot of people with severe psoriasis who would gladly take a 1:450 chance of death for a shot at 80%PASI90 and 50%PASI100.

I wasn't suggesting this was competition for Prurisol (but that would be nice...again...those hamsters say we have a chance.) It significantly raised the bar for the biologics. They can get a better understanding of risk factors for the drug and improve the risk profile of the drug as well. Keep in mind, even Prurisol needs at-risk patients screened out. Prurisol is just better understood due to long term Abacavir usage.